Total Payments
$310,452
2024 Payments
$13,355
Companies
27
Transactions
299
Medicare Patients
1,984
Medicare Billing
$377,500
Payment Breakdown by Category
Consulting$192,116 (61.9%)
Research$56,786 (18.3%)
Other$32,600 (10.5%)
Travel$20,642 (6.6%)
Food & Beverage$8,131 (2.6%)
Education$177.99 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $192,116 | 76 | 61.9% |
| Unspecified | $56,786 | 10 | 18.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,100 | 8 | 10.0% |
| Travel and Lodging | $20,642 | 69 | 6.6% |
| Food and Beverage | $8,131 | 132 | 2.6% |
| Honoraria | $1,500 | 1 | 0.5% |
| Education | $177.99 | 3 | 0.1% |
Payments by Type
General
$253,666
289 transactions
Research
$56,786
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $79,879 | 68 | $0 (2023) |
| Eli Lilly and Company | $63,030 | 20 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $42,910 | 57 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $33,372 | 42 | $0 (2023) |
| Merck Sharp & Dohme LLC | $15,127 | 9 | $0 (2023) |
| Lilly USA, LLC | $14,693 | 16 | $0 (2023) |
| Celgene Corporation | $9,901 | 11 | $0 (2024) |
| Janssen Biotech, Inc. | $8,108 | 16 | $0 (2022) |
| AbbVie Inc. | $8,050 | 5 | $0 (2023) |
| Janssen Global Services, LLC | $6,750 | 5 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,355 | 23 | AstraZeneca Pharmaceuticals LP ($9,850) |
| 2023 | $61,397 | 79 | Kite Pharma, Inc. ($12,227) |
| 2022 | $100,021 | 49 | Eli Lilly and Company ($50,519) |
| 2021 | $34,910 | 26 | Kite Pharma, Inc. ($16,493) |
| 2020 | $30,358 | 26 | Kite Pharma, Inc. ($19,594) |
| 2019 | $45,445 | 52 | Kite Pharma, Inc. ($16,211) |
| 2018 | $7,772 | 17 | Celgene Corporation ($4,202) |
| 2017 | $17,195 | 27 | Pharmacyclics LLC, An AbbVie Company ($9,907) |
All Payment Transactions
299 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $30.90 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Oncology | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $33.70 | General |
| Category: Oncology | ||||||
| 09/30/2024 | Elekta, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| 09/02/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 08/26/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $33.82 | General |
| Category: Oncology | ||||||
| 08/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $133.50 | General |
| Category: Oncology | ||||||
| 08/13/2024 | PFIZER INC. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,160.00 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $30.31 | General |
| 07/17/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $30.92 | General |
| Category: Oncology | ||||||
| 07/15/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $192.99 | General |
| Category: Oncology | ||||||
| 07/05/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| Category: Oncology | ||||||
| 07/01/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $32.45 | General |
| Category: Oncology | ||||||
| 06/15/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $52.20 | General |
| 05/07/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 04/23/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $33.83 | General |
| Category: Oncology | ||||||
| 03/11/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $30.93 | General |
| Category: Oncology | ||||||
| 02/16/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: Oncology | ||||||
| 02/14/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Oncology | ||||||
| 02/05/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $33.72 | General |
| Category: Oncology | ||||||
| 01/25/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $33.42 | General |
| Category: Oncology | ||||||
| 01/25/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $4.44 | General |
| Category: Oncology | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $553.29 | Research |
| Study: Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $457.79 | Research |
| Study: Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | Eli Lilly and Company | $41,524 | 1 |
| CC-5013-MCL-004 | Celgene Corporation | $3,689 | 1 |
| RV-LYM-PI-0247 - A phase II study of Revlimid in combination with Rituximab as initial treatment for patients with Indolent Non- Hodgkin's Lymphoma | Celgene Corporation | $3,444 | 1 |
| Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents | AstraZeneca Pharmaceuticals LP | $3,000 | 1 |
| A study related to non-Hodgkin lymphoma, compares the efficacy of obinutizumab in combination with chemotherapy versus rituximab- based treatments for untreated advanced cases (CL-NHL-13648) | Celgene Corporation | $1,411 | 1 |
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | Eli Lilly and Company | $1,082 | 1 |
| Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | F. Hoffmann-La Roche AG | $1,011 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 423 | 902 | $415,883 | $90,581 |
| 2022 | 8 | 463 | 904 | $359,925 | $86,631 |
| 2021 | 7 | 523 | 1,085 | $375,026 | $97,091 |
| 2020 | 7 | 575 | 1,327 | $471,915 | $103,197 |
Total Patients
1,984
Total Services
4,218
Medicare Billing
$377,500
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 255 | 612 | $326,670 | $65,379 | 20.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 48 | 159 | $45,277 | $14,593 | 32.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 24 | $14,298 | $3,224 | 22.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 50 | 60 | $10,230 | $2,992 | 29.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $13,526 | $2,786 | 20.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 25 | 26 | $5,882 | $1,608 | 27.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 204 | 515 | $265,242 | $59,751 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 87 | 128 | $32,150 | $9,513 | 29.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 28 | 90 | $25,470 | $7,444 | 29.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $10,838 | $2,921 | 27.0% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 62 | 84 | $9,730 | $2,305 | 23.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $7,098 | $2,015 | 28.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 37 | 41 | $6,719 | $1,922 | 28.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 12 | 13 | $2,678 | $760.17 | 28.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 192 | 500 | $247,308 | $58,374 | 23.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 35 | 146 | $41,318 | $12,211 | 29.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 97 | 136 | $33,686 | $11,204 | 33.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 103 | 169 | $26,514 | $8,032 | 30.3% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 69 | 107 | $12,069 | $3,183 | 26.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $8,296 | $2,353 | 28.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $5,835 | $1,734 | 29.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 200 | 630 | $300,199 | $52,861 | 17.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 76 | 308 | $87,164 | $26,238 | 30.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 47 | 52 | $26,805 | $8,652 | 32.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 96 | 147 | $21,382 | $6,240 | 29.2% |
About Dr. Luhua Wang, M.D
Dr. Luhua Wang, M.D is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417042722.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Luhua Wang, M.D has received a total of $310,452 in payments from pharmaceutical and medical device companies, with $13,355 received in 2024. These payments were reported across 299 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($192,116).
As a Medicare-enrolled provider, Wang has provided services to 1,984 Medicare beneficiaries, totaling 4,218 services with total Medicare billing of $377,500. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Houston, TX
- Active Since 10/03/2006
- Last Updated 06/29/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1417042722
Products in Payments
- Tecartus (Drug) $44,361
- CALQUENCE (Drug) $35,791
- IMBRUVICA (Drug) $26,088
- Imbruvica (Drug) $21,489
- Revlimid (Drug) $7,153
- VENCLEXTA (Drug) $5,950
- Non-Covered Product (Drug) $3,300
- ADCETRIS (Biological) $2,353
- Aliqopa (Drug) $2,248
- JCAR017 (Drug) $2,149
- TAZVERIK (Drug) $1,500
- EPKINLY (Drug) $1,400
- Epkinly (Drug) $772.98
- LUMOXITI (Biological) $700.00
- KEYTRUDA (Biological) $642.45
- Yescarta (Drug) $517.73
- BRUKINSA (Drug) $515.14
- DARZALEX (Biological) $454.36
- Ibrutinib (Drug) $124.72
- RYBREVANT (Drug) $117.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001